Precigen (PGEN) vs Supernus Pharmaceuticals (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precigen (PGEN) has outperformed Supernus Pharmaceuticals (SUPN) over the past year, gaining 127.8% versus a loss of 10.4%. Over five years, PGEN leads with a +62.2% price change compared with +36.0% for SUPN. Precigen is the larger company by market cap ($2.72 billion vs $2.45 billion), about 1.1 times the size.
Supernus Pharmaceuticals converts more of its revenue into profit, with a net margin of -5.4% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PGEN | SUPN |
|---|---|---|
| Share price | $7.60 | $42.14 |
| Market cap | $2.72B | $2.45B |
| 1-day change | +0.80% | -2.11% |
| YTD return | +80.38% | -13.38% |
| 1-year return | +127.79% | -10.44% |
| 5-year return | +62.15% | +35.98% |
| Forward P/E | — | 9.45 |
| EPS (TTM) | $-1.04 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.68M | $718.95M |
| Revenue growth (YoY) | +146.73% | +8.63% |
| Net income (latest FY) | $-250.64M | $-38.55M |
| Gross margin | — | 89.63% |
| Operating margin | -1141.13% | -8.66% |
| Net margin | -2588.21% | -5.36% |
| 52-week high | $8.98 | $59.68 |
| 52-week low | $2.99 | $40.51 |
| Distance from 52-week high | -15.37% | -29.39% |
| Analyst consensus | buy | none |
| Avg. price target upside | +79.61% | +46.54% |
| Average volume | 5.02M | 766.52K |
| Shares outstanding | 358.04M | 58.22M |
| Employees | 160 | 778 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed SUPN by 138.2 percentage points over the past year.
- Supernus Pharmaceuticals is more profitable, keeping -5.4 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs +8.63%).
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
About Supernus Pharmaceuticals
SUPN stock →Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Health Care · Biotechnology: Pharmaceutical Preparations · 778 employees
PGEN vs SUPN FAQ
Which is bigger, Precigen or Supernus Pharmaceuticals?
Precigen (PGEN) is larger, with a market capitalization of $2.72B compared with $2.45B for Supernus Pharmaceuticals (SUPN).
Which stock has performed better over the past year, PGEN or SUPN?
PGEN returned +127.79% over the past 12 months, compared with -10.44% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are Precigen and Supernus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.